IP Library Granted Patent US 7,105,530
Granted Patent B2
US 7,105,530 · App. 10/451,305 · Granted Sep 12, 2006

Pyrimidineamines as angiogenesis modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,530
App. No.
10/451,305
Granted
Sep 12, 2006
Kind
B2
Abstract

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Claims (16)

1. A compound of the formula:

or a salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

or a salt thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients.

3. The pharmaceutical composition of claim 2 , further comprising at least one additional agent that is an anti-neoplastic agent.

4. The pharmaceutical composition of claim 2 , further comprising an additional ggent that inhibits angiogenesis.

5. A method of treating a disorder in a mammal, said disorder being characterized by inaporooriate angiogenesis, wherein the disdrder is a proliferative retinopathy, comprising administering to said mammal a therapeutically effective amount of a compound of the formula:

or a salt thereof.

6. A compound of the formula:

or a salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

or a salt thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients.

8. The pharmaceutical composition of claim 7 , further comprising at least one additional agent that is an anti-neopiastic agent.

9. The pharmaceutical composition of claim 7 , further comprising an additional agent that inhibits angiogenesis.

10. A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, wherein the disorder is a proliferative retinopathy, comprising administering to said mammal a therapeutically effective amount of a compound of the formula:

or a salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: LEO OSPREY LIMITED
To: NOVARTIS AG
Reel/Frame 035771/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: GLAXOSMITHKLINE LLC
To: LEO OSPREY LIMITED
Reel/Frame 035762/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2011
From: LAUDEMAN, CHRISTOPHER P.
To: GLAXOSMITHKLINE LLC
Reel/Frame 025572/0681 →
CHANGE OF NAME Recorded Dec 15, 2009
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023649/0483 →